Health Canada reliance on foreign drug reviews

Summary#

The federal government made the Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs: SOR/2026-162. It lets Health Canada treat parts of some drug review files as already examined if certain foreign regulators have already done that work, with the aim of speeding up access to some drugs. The Order came into force on July 15, 2026.

What it does#

• Lets the Minister of Health “deem” that specified parts of a new drug submission, an abbreviated submission, or a supplement have been examined — based on a decision or documents from certain trusted foreign regulators — when several conditions are met.
• Covers three main pathways:
  • General Deeming: rely on an already-issued foreign authorization for certain classes of drugs.
  • 120‑day Filing: allow filing in Canada within 120 days of filing with a listed foreign regulator so Canadian review can be ready once the foreign decision is issued.
  • Joint Reviews: use documents produced during joint reviews with foreign regulators to shorten Canada’s portion of the examination.
• Requires the manufacturer to show key facts, including that the foreign regulator on the official list authorized the foreign drug, and that the Canadian product would have the same medicinal ingredient(s), strength, dosage form and route of administration as that foreign product.
• Requires manufacturers to provide the most recently approved foreign labels, to identify any differences with the foreign drug, and to show those differences would not affect safety or effectiveness; if differences could matter, that part of the submission will be fully reviewed in Canada.
• Uses a published reference list (the “IbR List”) that names which drug classes and which foreign regulatory authorities (FRAs) qualify; that list can be updated over time.
• Keeps important Canadian checks: Health Canada still reviews Canadian-specific items such as labelling, product monographs and risk‑management material, and the Minister keeps the final decision on whether to authorize a product.
• Does not apply to public health emergency drugs, extraordinary‑use pathways, or some emergency access routes.

Who's affected#

• Drug manufacturers that already have, or can get, authorizations or review documents from the foreign regulators on the official list. This includes companies that make new drugs, generics and biosimilars — but only when the submission fits the Order’s rules.
• Health Canada staff and reviewers, who will use this tool to reallocate some review effort.
• Patients, clinicians and health-system bodies (including health technology assessment organizations) who may see some drugs reach Canada sooner.
• Domestic manufacturers that sell mainly in Canada may feel increased competition if more foreign‑approved drugs are brought to Canada using this pathway.
• Veterinary drug makers (the Order covers some animal drugs too) and related professional groups.
• Smaller Canadian companies are less likely to use the Order because they typically do not hold foreign authorizations to rely on.

Why it matters#

• Faster access: the Order is intended to shorten review time for some submissions — Health Canada expects some files using full reliance for the main technical sections could be up to 40% quicker in review time.
• Lower industry burden: Health Canada estimated an average net benefit to industry of about $18,075 per submission that uses deeming (gross savings of $27,675 from fewer information requests minus about $9,600 to prepare the eligibility/differences material). It also expects about 1.5 fewer information requests per applicable submission.
• Encourages earlier filing: the 120‑day option is meant to reduce the delay between filings abroad and filing in Canada, helping Canadians get access sooner.
• Safety and oversight remain: the Order requires evidence and lets Health Canada examine Canada‑specific elements. The Minister can still refuse or request full examinations if safety concerns appear.
• Uncertainties and trade-offs: Health Canada cannot reliably predict how many submissions will use the Order. The measure could increase competition that affects Canadian firms and will change some workloads for regulatory reviewers and reimbursement evaluators. The government plans to monitor effects and update the official list and guidance over time.
• Practical timing note: new rules about required risk management plans for some human drugs take effect on April 1, 2027, and will be handled alongside this Order.